Cristcot to Present Oral Abstract at 2026 Digestive Disease Week (DDW)

Oral presentation on the impact of concomitant steroid use in ulcerative colitis (UC) scheduled for May 5, 2026, at 9:30am CDT

AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company will present its abstract evaluating the impact of concomitant steroid use in ulcerative colitis (UC) at the 2026 Digestive Disease Week (DDW) Annual Meeting being held May 2-5 in Chicago, Illinois. DDW is a leading forum for experts in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, bringing together clinicians, researchers, and pharmaceutical leaders to showcase the latest advancements in the field.

“It is an honor to gather with so many renowned global thought leaders who share our commitment to discovering innovative treatments across digestive diseases,” said Dr. Raj Devarajan, Global Medical Advisor, Cristcot. “The pharmacokinetic (PK) and HPA-axis dysregulation resulting from exogenous use of corticosteroids in inflamed intestinal mucosa has not been completely characterized. Cristcot’s CESSA trial aimed to evaluate this phenomenon in the process of our safety monitoring. This study offers a glimpse into the potential future of IBD research to more precisely examine the Study Drug efficacy and safety without the interference of surreptitious use of corticosteroids.”

Details of the oral presentation are as follows:

Session Type: Abstract Presentation
Title: Surreptitious Corticosteroid Use Identified by Formal Pharmacokinetic and HPA-Axis Testing in a Phase 3 Ulcerative Colitis Clinical Trial Session
Date & Time: May 5, 2026, at 9:30am CDT
Presenter: Parambir Dulai, MD

About ngHCA

ngHCA, Cristcot’s investigational hydrocortisone acetate (HCA) 90 mg suppository formulation, is a novel corticosteroid therapy delivering a small volume suppository administered using the Sephure^® suppository applicator. Rectally administered topical treatments, including topical corticosteroids, are important treatment options (either alone or in combination with other therapies), for directing delivery to inflammation sites and limiting systemic drug exposure. Unlike other corticosteroid treatments, Cristcot's advanced HCA formulation allows for rapid, sustained release with optimal bioavailability, and very limited systemic exposure. Cristcot’s innovative delivery system is designed to overcome the treatment barriers associated with currently available therapies and enhance patient compliance. If approved by FDA, ngHCA would be the first and only FDA-approved HCA suppository.

About Ulcerative Colitis (UC)

UC is a life-long, chronic gastrointestinal autoimmune disease characterized by inflammation and ulcers in the lining of the large intestine, including the rectum and sometimes, all or part of the colon. Symptoms include rectal bleeding, profuse diarrhea, bowel urgency, tenesmus, and abdominal pain significantly impacting patients' quality of life. UC flares originate in the rectum, and if left untreated, inflammation can progress to more proximal disease and severity, leading to hospitalization or surgery. There is no cure for UC, and breakthrough flares, even while taking maintenance medication, is a known pattern of the disease profile. Over 80% of UC patients experience two flares annually, with many reporting debilitating effects on daily activities, work, and mental health. Despite existing treatments, patients experience intermittent flares and often change therapies as a measure to treat increased disease activity. The time of transition between one treatment to another is further complicated while waiting for the new therapy to reach full efficacy potential.

About Cristcot

Cristcot is a clinical-stage pharmaceutical company dedicated to advancing targeted therapies for gastrointestinal diseases. The Company's lead asset, ngHCA, is positioned to become an important therapeutic option for ulcerative colitis patients. Cristcot's diversified pipeline includes investigational development programs for ulcerative colitis, acute pancreatitis, hemorrhoid disease and other inflammatory gastrointestinal indications with an emphasis on innovative, patient-centric solutions. The company is headquartered in Austin, Texas.

For more information, please contact us via email or connect with us on LinkedIn.

Forward-Looking Statements

Certain information set forth in this press release contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements). Examples of forward-looking statements include, but are not limited to, statements regarding the (i) projected financial performance of the Company; (ii) market prospects and potential future sales for the Company products; (iii) expected development of the Company's products, business and projects; (iv) availability of competing products in the market; (v) prospects for regulatory approval of the Company's products; (vi) execution of the Company's vision and growth strategy; and (vii) availability of protections under applicable intellectual property laws.

These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Contacts

Jenny Gizzi, Chief Administrative Officer
Cristcot
E: jenny.gizzi@cristcot.com

Investor Relations

Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.